CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Fisher Micro

Fisher Micro is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Olean General Hospital

Olean General Hospital/Bradford Regional Medical Center is a healthcare provider offering primary and specialty care to residents in southwestern New York state and northwestern Pennsylvania.

Gulf Coast Center

Gulf Coast Center is a Galveston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VPX Sports Nutrition

VPX Sports Nutrition is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

RaNA Therapeutics

RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.